What is IMNN stock price today?

IMNN (Imunon Inc) stock is trading at $3.18 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is IMNN stock going up or down today?

IMNN stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy IMNN stock now?

The decision to buy IMNN depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is IMNN a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for IMNN based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is IMNN stock overvalued or undervalued?

Use our DCF valuation calculator to determine if IMNN is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is IMNN's P/E ratio?

P/E ratio data for IMNN will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is IMNN's market cap?

IMNN (Imunon Inc) has a market capitalization of $0.01 billion, making it a small-cap stock.

What is IMNN's price to book ratio?

IMNN trades at a price-to-book (P/B) ratio of 1.64, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does IMNN pay dividends?

IMNN does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is IMNN's dividend yield?

IMNN does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is IMNN stock a good long-term investment?

IMNN's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is IMNN's revenue growth rate?

Revenue growth data for IMNN is available on our dashboard with detailed financial statement analysis.

Profitability metrics for IMNN are available on our dashboard with complete income statement analysis.

What are the risks of investing in IMNN?

Key risks for IMNN include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does IMNN compare to its competitors?

Compare IMNN to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize IMNN's performance and positioning.

What is IMNN's stock price target for 2026?

Our AI model provides price targets for IMNN based on fundamental analysis: Bull case $4.13 (+30%), Base case $3.66 (+15%), Bear case $2.86 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about IMNN?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for IMNN. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is IMNN's next earnings report?

IMNN reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

IMNN - Imunon Inc

NYSE * Health Care * Biotechnology

$3.18

+$0.08 (+2.58%)

About Imunon Inc

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

IMNN Key Statistics

Market Cap

$12.16M

P/B Ratio

1.64

EPS

$-6.83

Employees

How IMNN Compares to Peers

IMNN is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
IMNN(This stock)	$12.16M	N/A	0%	0.0%	-
AMGNAmgen Inc	$189.19B	24.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$174.33B	20.7	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.01B	29.0	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.87B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.50B	20.5	-0%	0.1%	vs BIIB

Imunon Inc Company Information

Headquarters: New Jersey; U.S.A
Website: imunon.com
Sector: Health Care
Industry: Biotechnology

IMNN - Imunon Inc

About Imunon Inc

IMNN Key Statistics

How IMNN Compares to Peers

Imunon Inc Company Information

IMNN Lician Score

IMNN Financial Snowflake

Upcoming Events for IMNN